LONDON, United Kingdom: Syncona Limited, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, announced that its newly established portfolio company has successfully completed its previously announced acquisition of Applied Genetic Technologies Corporation (“AGTC”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialisation…
ArcticZymes Technologies appoints Dr. Darren Ellis as Chief Scientific Officer (CSO)
TROMSØ, Norway: ArcticZymes Technologies ASA (OSE: AZT) announced the appointment of Dr. Darren Ellis as its first Chief Scientific Officer (CSO). ArcticZymes Technologies has today appointed Dr. Darren Ellis as its first Chief Scientific Officer. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and ThermoFisher Scientific) in leading and…
AstraZeneca announces sale of West Chester site
LONDON, United Kingdom: AstraZeneca announced the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines. Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca, said: “As part of our long-term strategy to ensure our global supply network remains fit…
Careem completes a billion ride hailing trips across the Middle East, North Africa and Pakistan
KARACHI, PAKISTAN: Careem, the region’s leading multi-service platform, celebrates 1 billion ride hailing trips across the Middle East, North Africa and Pakistan. Careem Captains have driven over 9 billion kilometres across more than 80 cities over ten years. The countries with the highest number of rides recorded are Pakistan (299 million), Saudi Arabia (242 million),…
Cambridge Cognition forms partnership with Luca Healthcare for Chinese Market Expansion
LONDON, UK: Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announced an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited. Luca Healthcare is a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing…
GPE announces fashion retailer Reserved signs new flagship store
LONDON, United Kingdom: Great Portland Estates (GPE) has announced that fashion retailer, Reserved, has leased a new London flagship within its prestigious development at 70/88 Oxford Street. Alongside Boom: Battle Bar, this deal takes GPE’s retail lettings to 96% let or under offer. Reserved will occupy 19,645 sq ft over the ground and first floors….
East Imperial signs The Lion Brewery as its US bottling partner
LONDON, United Kingdom: East Imperial, the global purveyor of ultra-premium beverages, announce the appointment of The Lion Brewery as its US bottling partner. Under the terms of the agreement, The Lion Brewery will bottle East Imperial’s entire range, including the award-winning Grapefruit Tonic, Mombasa Ginger Beer and Yuzu Lemonade. Bottling is expected to start in…
Rapid Nutrition to acquire a notable wellness business
PARIS, FRANCE: Rapid Nutrition PLC (Euronext Growth: ALRPD), has entered into discussions to acquire a successful beauty business, recognised across the globe for its innovative and sustainable products supported by significant customer base. A natural wellness company focused on organic wholefood-based nutrition and science-based herbal products with growing worldwide distribution, Rapid Nutrition continues to accelerate…
Nicox raises €10 million in private placement
SOPHIA ANTIPOLIS, France: Nicox SA, an international ophthalmology company, today announced a financing through a private placement via the issuance of 6,849,316 new ordinary shares, each share with an attached warrant to acquire 6,849,316 additional new ordinary shares, at an offering price of €1.46 per share and associated warrant exercisable at a price of €1.70…
Paradigm Biopharmaceuticals CEO, Marco Polizzi, to step down
SYDNEY, Australia: Paradigm Biopharmaceuticals, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, announced that its CEO, Mr Marco Polizzi, has stepped down from his role and will cease employment with the Company on 20 February 2023. The Paradigm Board said “The Paradigm Board would like to thank Mr…